Insider Trading Alert - MCK, MMC And AT Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 28, 2015, 91 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $529.45 to $86,394,898.20.

Highlighted Stocks Traded by Insiders:

McKesson (MCK) - FREE Research Report

Schechter Lori A., who is EVP, GC & Chief Compl. Officer at McKesson, sold 1,468 shares at $238.22 on May 28, 2015. Following this transaction, the EVP, GC & Chief Compl. Officer owned 809 shares meaning that the stake was reduced by 64.47% with the 1,468-share transaction.

The shares most recently traded at $238.50, up $0.28, or 0.12% since the insider transaction. Historical insider transactions for McKesson go as follows:

  • 4-Week # shares sold: 1,014
  • 12-Week # shares sold: 1,014
  • 24-Week # shares sold: 1,014

The average volume for McKesson has been 968,800 shares per day over the past 30 days. McKesson has a market cap of $55.4 billion and is part of the services sector and wholesale industry. Shares are up 14.58% year-to-date as of the close of trading on Thursday.

McKesson Corporation delivers pharmaceuticals, medical supplies, and health care information technologies to the healthcare industry in the United States and internationally. The company operates in two segments, McKesson Distribution Solutions and McKesson Technology Solutions. The stock currently has a dividend yield of 0.4%. The company has a P/E ratio of 38.1. Currently, there are 14 analysts who rate McKesson a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MCK - FREE

TheStreet Quant Ratings rates McKesson as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full McKesson Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

How World's Largest Drug Distributor Is Helping Harvey Victims Treat Snakebites

J&J Enters Death Penalty Debate, Protests Use of Drug in Lethal Injection

Eclipse in the USA: Then and Now

Finding Value in a Pricey Environment

Allscripts Stock Climbs, Cantor Upgrades After McKesson Deal